Kiora Pharmaceuticals (KPRX) Equity Average (2016 - 2025)
Kiora Pharmaceuticals (KPRX) has disclosed Equity Average for 11 consecutive years, with $22.3 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Equity Average fell 29.45% year-over-year to $22.3 million, compared with a TTM value of $22.3 million through Sep 2025, down 29.45%, and an annual FY2024 reading of $15.9 million, changed N/A over the prior year.
- Equity Average was $22.3 million for Q3 2025 at Kiora Pharmaceuticals, down from $22.9 million in the prior quarter.
- Across five years, Equity Average topped out at $34.0 million in Q2 2024 and bottomed at $7.1 million in Q4 2023.
- Average Equity Average over 5 years is $17.5 million, with a median of $15.2 million recorded in 2021.
- The sharpest move saw Equity Average plummeted 37.85% in 2022, then soared 292.51% in 2024.
- Year by year, Equity Average stood at $16.0 million in 2021, then tumbled by 39.6% to $9.6 million in 2022, then dropped by 26.29% to $7.1 million in 2023, then skyrocketed by 292.51% to $27.9 million in 2024, then fell by 20.17% to $22.3 million in 2025.
- Business Quant data shows Equity Average for KPRX at $22.3 million in Q3 2025, $22.9 million in Q2 2025, and $24.7 million in Q1 2025.